Investing.com -- Appian Corp (NASDAQ:APPN) shares rose 1% in Wednesday trading following a regulatory disclosure from activist hedge fund Fivespan Partners, LP. The San Francisco-based firm revealed a 6.2% stake in the enterprise software provider, according to a 13D filing submitted late Tuesday.
The hedge fund now controls 2,630,907 total shares, signaling a significant push into the low-code automation space. "The Reporting Persons acquired the securities of the Issuer reported herein based on their belief that the securities were undervalued and represented an attractive investment opportunity," the filing stated.
Evaluate activist picks with analysis tools by upgrading to InvestingPro - get 55% off today
Fivespan’s entry comes as Appian faces increasing pressure to revitalize a stock price that has struggled following a dramatic valuation reset from its pandemic-era heights. The stock reached an all-time high of $235.24 in January 2021 before a broader rotation away from high-multiple, unprofitable tech names triggered an 86% decline over the past 5 years.
Fivespan indicated it intends to engage deeply with management on issues ranging from capital allocation to board composition and mergers and acquisitions. According to the filing, discussions "will cover a range of issues, including those relating to the business of the Issuer, management, board composition (which include whether it makes sense for a Fivespan employee to be on the Issuer’s board of directors), investor communications, operations, capital allocation, dividend policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation, and corporate governance."
The move mirrors Fivespan’s recent activity at Qiagen NV (NYSE:QGEN), where the fund successfully placed operating partner Mark Stevenson on the board. Stevenson, a former Thermo Fisher Scientific executive, is now viewed by some speculators as a potential candidate for Qiagen’s top role, as the company is seeking a permanent successor for outgoing chief executive Thierry Bernard.
Additionally, Bloomberg recently reported that Qiagen is exploring strategic options, including a sale, though it is unclear how much influence Fivespan is exerting as the company reviews alternatives.
Both Fivespan and Appian have yet to respond to Investing.com’s request for commentary.































